Multiplexed, microscale, microarray-based serological assay for antibodies against all human-relevant coronaviruses
This article has been Reviewed by the following groups
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
- Evaluated articles (ScreenIT)
Abstract
No abstract available
Article activity feed
-
-
SciScore for 10.1101/2020.09.03.20179598: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement Consent: Deidentified specimens from Mount Sinai Icanh School of Medicine (New York, NY) were obtained under a license agreement which indicates appropriate IRB approval and informed consent for the specimens provided. Randomization not detected. Blinding Testing personnel were blinded to these orthogonal results prior to completing VaxArray CoV SeroAssay analysis. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Antibodies Sentences Resources 2.2 Linear Dynamic Range and Lower Limit of Quantification Analysis: A study to determine the lower limit of quantification and linear dynamic range of the different capture antigens … SciScore for 10.1101/2020.09.03.20179598: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement Consent: Deidentified specimens from Mount Sinai Icanh School of Medicine (New York, NY) were obtained under a license agreement which indicates appropriate IRB approval and informed consent for the specimens provided. Randomization not detected. Blinding Testing personnel were blinded to these orthogonal results prior to completing VaxArray CoV SeroAssay analysis. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Antibodies Sentences Resources 2.2 Linear Dynamic Range and Lower Limit of Quantification Analysis: A study to determine the lower limit of quantification and linear dynamic range of the different capture antigens represented was executed using monoclonal antibodies that target the spike proteins of SARS-CoV-1 (MRO-1214LC, CR3022 MRO-1214LCsuggested: NoneThe CR3022 antibody targeting SARS-CoV-1 is known to bind the the nCoV(ii) RBD antigen, the SARS antigen (and the nCoV(i) full-length spike antigen to a much weaker extent), and the SARS-CoV-2 Genetex antibody is known to bind the nCoV(i) full-length spike antigen (and the nCoV(iii) S2 antigen to a much weaker extent). CR3022suggested: NoneS2suggested: NoneThe four antibodies were mixed, and a 13-point serial dilution in Protein Blocking Buffer and three blank wells containing Protein Blocking Buffer without antibody were prepared, with each sample subsequently analyzed on the VaxArray CoV SeroAssay according to the operation manual with one exception: because the anti-SARS-CoV1 antibodies are human antibodies and the other three antibodies are mouse antibodies, antibodies were detected with a mixture of anti-mouse and anti-human IgG secondary antibody labels (VXCV-7620 and VXCV-7326, InDevR, Inc., respectively). anti-SARS-CoV1suggested: Noneanti-mousesuggested: Noneanti-human IgGsuggested: NoneBecause monoclonal antibodies binding to the OC43, NL63, or 229E capture antigens were not available at the time of testing, linearity and limit of detection for these 3 capture antigens was explored using a limiting endpoint dilution series of a pooled human serum sample known to be positive for antibodies to all four human CoVs: OC43, NL63, HKU1, and 229E. HKU1suggested: NoneNo monoclonal antibodies were available at the time of testing that target OC43, NL63, or 229E, and so specificity for these capture antigens was not assessed. NL63suggested: NoneA total of 132 serum samples known to be negative for the presence of antibodies to SARS-CoV-2 based on date of collection prior to December 2019, including 33 specimens from pediatric donors age 2-16, were analyzed via the standard VaxArray CoV SeroAssay procedure at a 1:100 dilution in PBB. 2.4 Reproducibility and Accuracy: To assess reproducibility and accuracy, a pooled human serum sample known to be positive for antibodies to SARS-CoV-2 (and known to bind all 3 SARS-CoV-2 antigens on the microarray) and all 4 of the endemic coronaviruses (HKU1, OC43, NL63, and 229E) was prepared in adequate volume to run a large number of replicates. SARS-CoV-2suggested: NoneResults from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
